🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Betty Wang, MD, (Betty Wang) recaps 3 key urologic cancer studies from #EAU25. | Cleveland Clinic Urology Sign up🔐 to hear her thoughts: urologytimes.com/view/betty-wan…

Massive shoutout to Devika Nandwana as she wraps up an incredible year with the Bukavina Lab! From leading as our research coordinator extraordinaire to pioneering #microplastics research with her Case Western Reserve engineering brilliance 💯we truly couldn’t have done it without you Sahab Ram

Strong Cleveland Clinic Urology Team presence at #AUA2025 . Leading the way in urologic care, discovery, and education

Monday morning | #AUA25 presentations with john lee, Nicholas Heller, PhD, Will Jevnikar & Rebecca Campbell

Really interesting work by Betty Wang looking at gender of first and last author on urology publications: ↗️Female-Female (FF) author publications growing over time ↙️FF author combo under-cited even though the altmetric attention score is higher and equitable funding #AUA25

Our stellar Cleveland Clinic Urology resident Eiftu #BlackLivesMatter Haile presenting our work on performance of isoPSA in Black and non-white men Interestingly, it seems to perform better! Keep an eye out for her!! #AUA2025 Robert Abouassaly,MD Chris Weight Alp Tuna Beksac Betty Wang Sam Haywood Jason Scovell

Super excited to have Henning Plage visiting us at Cleveland Clinic Urology! Can’t wait to show off our awesome team and learn a thing or two from our European Association of Urology (EAU) friend 🇩🇪🇺🇸Chris Weight Rebecca Campbell Betty Wang

Excited to have the important work going on at Bukavina Lab featured by Urology Times. Laura Bukavina Betty Wang

In Eur Urol Focus, we show that grade group 3 (GG3) prostate cancers are heterogeneous. Unfavorable histology (EC or IDC) was strongly associated with recurrence after surgery, independent of % pattern 4 and CAPRA-S, and may improve risk stratification. pubmed.ncbi.nlm.nih.gov/40374413/.

At the tail end of research year and things are finally starting to be cranked out… 😂 check out this resource for your patients interested in Adstiladrin!!!

This deserves a post of its own 🥹 Dogs are so pure we don’t deserve them

🧬 Practice-changing insights👇 ctDNA role in high risk NMIBC ( T1HG and BCG unresponsive). First pub Cleveland Clinic Urology as we continue to learn more -- ctDNA is detectable in 35% of highest-risk NMIBC 💥 ctDNA+ often flags recurrence or upstaging ~3mo before imaging. In BCG-naïve:

Our Cleveland Clinic Urology clinical and research fellows enjoying a pre game dinner 🥘 w/ Phil Abbosh Fox Chase Cancer Center Rebecca Campbell Betty Wang Can Aydogdu can’t wait for tomorrow 🧫🔬🧬 #U54ROBIN luminary lecture series

Hosted our #ProstateCancer Active Surveillance Retreat at @FarenheitCLE 🔥making big research plans for future of AS 🔥 Proud of our Prostate Cancer Working Group!! Cleveland Clinic Urology Chris Weight Sam Haywood Jane K Nguyen MD PhD Andrei Purysko Dr. J. Kaouk Jamal Alamiri Eiftu #BlackLivesMatter Shalini Moningi

Final requirement of fellowship met ✅ Climbing with Chris Weight (following a post chemo RPLND)

Betty Wang, MD, (Betty Wang) and Laura Bukavina, MD, MPH, MSc, (Laura Bukavina) highlight a study assessing ctDNA’s role in NMIBC. Cleveland Clinic Urology urologytimes.com/view/investiga…